Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma

Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials

(2020) Wei Zhang et al.   Expert Review of Clinical Pharmacology

Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer—A Nationwide, Population-Based, Propensity Score-Matched Cohort Study

(2020) Shih-Yi Lin et al.   Cancers

Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments

(2020) Marcos V. Perini et al.   PHARMACOLOGY & THERAPEUTICS

Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities

(2019) Chelsea C. Estrada et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

(2019) Yanxia Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of hypoxia signalling: new implications for nephrology

(2019) Johannes Schödel et al.   Nature Reviews Nephrology

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

(2019) Tatsuya Yamashita et al.   JOURNAL OF GASTROENTEROLOGY

Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes

(2019) Yifei Zhong et al.   Nature Communications

Not all proteinuria is created equal

(2019) Andrew Beenken et al.   JOURNAL OF CLINICAL INVESTIGATION

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

(2019) Amy Lee et al.   Frontiers of Medicine

A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non–small-cell Lung Cancer

(2018) Fengying Wu et al.   Clinical Lung Cancer

Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer

(2018) Zuhua Chen et al.   Journal of Hematology & Oncology

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

(2018) Jianming Xu et al.   CLINICAL CANCER RESEARCH

VEGF expands erythropoiesis via hypoxia-independent induction of erythropoietin in noncanonical perivascular stromal cells

(2018) Alissa C. Greenwald et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance

(2017) Fang Li et al.   EUROPEAN JOURNAL OF CANCER

Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production

(2017) Masaki Nakamura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apatinib is effective for treatment of advanced hepatocellular carcinoma

(2017) Yinlong Kong et al.   Oncotarget

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Positive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma

(2016) Hong Yao et al.   CANCER LETTERS

Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein

(2016) Shanshan Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

(2016)   JOURNAL OF HYPERTENSION

Erythropoietin Stimulates Tumor Growth via EphB4

(2015) Sunila Pradeep et al.   CANCER CELL

'Pre-cachexia': a non-existing phenomenon in cancer?

(2014) S. Blauwhoff-Buskermolen et al.   ANNALS OF ONCOLOGY

Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib

(2014) Stephanie Lankhorst et al.   HYPERTENSION

Tubulovascular Cross-Talk by Vascular Endothelial Growth Factor A Maintains Peritubular Microvasculature in Kidney

(2014) H. Dimke et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

(2014) Bradley J Monk et al.   LANCET ONCOLOGY

Strategies for the management of adverse events associated with mTOR inhibitors

(2014) Bruce Kaplan et al.   Transplantation Reviews

Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy

(2013) Hassan Izzedine et al.   KIDNEY INTERNATIONAL

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Use of Angiotensin Receptor Blockers and the Risk of Cancer

(2012) Laurent Azoulay et al.   PLoS One

Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database

(2012) K. Bhaskaran et al.   BMJ-British Medical Journal

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

(2011) Shu Tian et al.   CANCER SCIENCE

The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression

(2011) B. D. Hedley et al.   CLINICAL CANCER RESEARCH

Unknown

(2011) Chun Liu et al.   MOLECULAR MEDICINE

Erythropoietin receptor contributes to melanoma cell survival in vivo

(2011) S M Kumar et al.   ONCOGENE

Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice

(2011) Giovambattista De Sarro et al.   PHARMACOLOGICAL RESEARCH

Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters

(2010) Y.-j. Mi et al.   CANCER RESEARCH

Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial Infarction

(2010) Florian Leuschner et al.   CIRCULATION RESEARCH

Captopril modulates hypoxia-inducible factors and erythropoietin responses in a murine model of total body irradiation

(2010) Michal Barshishat-Kupper et al.   EXPERIMENTAL HEMATOLOGY

Glomerular Structure and Function Require Paracrine, Not Autocrine, VEGF-VEGFR-2 Signaling

(2010) K. Sison et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease

(2010) Delma Veron et al.   KIDNEY INTERNATIONAL

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

(2010) Sripal Bangalore et al.   LANCET ONCOLOGY

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

(2009) Faina Gurevich et al.   AMERICAN JOURNAL OF MEDICINE

VEGF Inhibition and Renal Thrombotic Microangiopathy

(2008) Vera Eremina et al.   NEW ENGLAND JOURNAL OF MEDICINE